Today, Stan Wong commented about whether XLF-N, DECK-N, AAPL-Q, SLF-T, MFC-T, XDIV-T, CCO-T, UBER-N, VFV-T, XEI-T, VDY-T, JPM-N, GS-N, BAC-N, DOL-T, CAH-N, ASML-Q, NVDA-Q, LLY-N, NVO-N, COST-Q, WMT-N, SBUX-Q, BCE-T, RCI.B-T, CNQ-T are stocks to buy or sell.
Removed from his portfolio not long ago on a stop loss. Long term, secular growth of anti-obesity drugs is still strong. Short-term, cyclical challenges. Quite leveraged to anti-obesity and diabetes, but LLY is more diversified.
Once negative sentiment dissipates, could see him getting back in. About 20-25% earnings growth, trading at 22x, so PEG is just under 1. Value is there, but sentiment not in its favour right now.
Fantastic earnings growth. Just bounced off 200-day MA (a good support level), and that's where he added recently. Paying about 32x forward PE for 35% expected growth, so the PEG ratio is reasonable.
DeepSeek news concerned some investors, but does it make the products that NVDA does with the same broad customer base? Have to see over coming quarters and years.
The S&P 500 index, but in Canadian dollars. Not expensive at 9 bps MER. But, as he's pointed out before, the S&P has about 37% bunched up around 10 names (with 8 of those being tech names). So you can think it's extremely diversified, but it's not.
He's not saying not to own it, but you need to know what you're buying compared to what you already own in your portfolio.
Let's look at the chart, as the first thing you do is check the technical structure. Stock's not only come down, but also fallen below the 200-day MA. The 200-day MA, itself, is starting to go sideways and downwards. Weakening. Guided lower on earnings.
Expected earnings growth rate is very strong double digits, and the PE isn't bad at 27x. However, the chart's telling you something different. Chart for much of 2023 and 2024 had been sideways. Potential for regulation to come along and hurt profits.
High valuation, but paying a premium for a name that has scale and not many competitors.